The experience of using mepolizumab in severe bronchial asthma


DOI: https://dx.doi.org/10.18565/pharmateca.2019.11.85-88

G.R. Sergeeva, A.A. Znakhurenko, E.V. Leshenkova, A.V. Emelyanov

North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia
Background. The treatment of patients with severe bronchial asthma using monoclonal antibody preparations against key cytokines involved in the development of asthma is a new area of therapy and requires careful selection of patients based on clinical features and biological markers. Currently, five biological preparations have been registered in the Russian Federation for the treatment of patients with the T2-endotype of bronchial asthma, the clinical experience of their use, in particular mepolizumab, is relatively limited.
Description of the clinical case. A female patient with uncontrolled severe bronchial asthma at the step 5 treatment (high doses of inhaled glucocorticosteroids, long-acting β2-adrenoagonists, long-acting anticholinergics, oral glucocorticosteroids), with elevated eosinophilic inflammation biomarker levels (blood eosinophils, total IgE), and low lung function received drug mepolizumab during the year in addition to baseline therapy.
Conclusion. As a result of treatment, an improvement in disease control and quality of life was observed; it was possible to reduce the dose of oral glucocorticosteroids by more than 2 times and significantly reduce the use of healthcare resources.
Keywords: severe bronchial asthma, biological therapy, mepolizumab, clinical case

About the Autors


Corresponding author: Alexander V. Emelyanov, MD, Professor, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; е-mail: aleksandr.emelyanov@szgmu.ru
Address: 41, Kirochnaya Street, St. Petersburg 191015, Russian Federation


Бионика Медиа